Medifast, Inc.

Medifast, Inc. reported a challenging fiscal year 2025 with revenue of $385.8 million. The company generated a gross profit of $275.2 million, representing a gross margin of 71.3%. However, selling, general, and administrative expenses of $289.4 million resulted in an operating loss of $14.2 million. Total other income of $8.6 million, primarily from interest income of $5.5 million, partially offset the operating loss, leading to a loss before income taxes of $5.6 million. After an income tax expense of $13.0 million, the company reported a net loss of $18.7 million, or a loss per share of $2.00 (basic and diluted). Despite the net loss, operating activities generated positive cash flow of $6.9 million. The company ended the year with total assets of $248.0 million, including $89.3 million in cash and cash equivalents, and maintained a strong equity position of $198.9 million against total liabilities of $49.1 million.

Key Takeaways